CURRENT REPORT 18/2023
April 20th, 2023

Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS

The Management Board of Ryvu Therapeutics S.A. ("Company", "Ryvu") informs that on April 20th, 2023 it entered into two agreements with Labcorp Drug Development Inc. (Labcorp), based in New Jersey, USA to conduct Phase II study start-up services for the clinical development of RVU120 in hematologic malignancies: (i) RIVER-52 (in patients with AML/HR-MDS; RVU120 monotherapy) and (ii) RIVER-81 (in patients with AML; RVU120 combination), (the "Agreements").

The commencement of both aforementioned Phase II studies in AML/HR-MDS is expected in H2 2023. The start-up activities covered by the Agreements outlined above, constitute the second and third RVU120 Phase II studies planned to be initiated by the end of 2023 and are parts of the planned broad RVU120 clinical development across multiple indications (hematology and solid tumors) and in diverse treatment settings (monotherapy and combination therapy), aimed at maximizing the potential of RVU120 and diversifying development risks. Additional clinical trials investigating RVU120 in patients with low-risk MDS or with an MDS/MPN overlap syndrome are in planning.

The estimated total cost of services under Agreements is EUR 1,221,627.57 (PLN 5,632,802.56 converted at the average exchange rate of the National Bank of Poland of April 20th, 2023, EUR 1 = PLN 4.6109). The value of Agreements may change in the event of extending the scope of the order.

Labcorp is a leading global life sciences company with 25 years of experience in conducting clinical trials to support drug development. Over the past five years, Labcorp has conducted more than 1,000 clinical studies in Oncology, with Phase I/II studies being the most common.

RVU120 is a clinical-stage, highly selective, first-in-class inhibitor of CDK8 and CDK19 kinases. RVU120 has demonstrated efficacy in a number of *in vitro* and *in vivo* models of solid tumors and hematologic malignancies and early signs of clinical activity in patients. Two dose-finding studies are currently ongoing investigating RVU120 in patients with solid tumors and with AML or HR-MDS. The ongoing Phase Ib study in AML/HR-MDS is currently enrolling at seven investigational sites in Poland and the USA.

The start-up agreements meet the criteria of significant agreements due to their importance for the further development of the RVU120 program. In particular, Ryvu points out that extension of the clinical development in hematologic malignancies by initiating Phase II clinical trials investigating RVU120 in AML/HR-MDS as a monotherapy (RIVER-52 study) and in combination (RIVER-81 study), was one of the goals indicated in the Development Plans for 2022-2024, which the Company announced in

the current report 16/2022 on August 19th, 2022. The terms of the Agreements do not differ from those customary for this type of contract.

Legal basis: art. 17.1 of MAR

Representatives of the Company:

- Hendrik Nogai – Member of the Management Board
- Kamil Sitarz – Member of the Management Board